Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company’s products include Opdivo for various anti-cancer indicat... Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. Bristol-Myers Squibb Company has a strategic collaboration with Arcus Biosciences, Inc. to develop a novel treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.875 | 1.80430972265 | 48.495 | 50.2 | 48 | 3807 | 48.89243158 | DE |
| 4 | 0.915 | 1.88835001548 | 48.455 | 51.71 | 46.575 | 3589 | 49.00718663 | DE |
| 12 | -0.77 | -1.53570003989 | 50.14 | 53.5 | 46.575 | 4197 | 49.78179027 | DE |
| 26 | 5.445 | 12.3961297666 | 43.925 | 53.71 | 43.2 | 6011 | 49.034276 | DE |
| 52 | 5.79 | 13.2859109683 | 43.58 | 53.71 | 36.2 | 8877 | 42.85602594 | DE |
| 156 | -11.13 | -18.3966942149 | 60.5 | 61 | 36.2 | 8183 | 44.93926862 | DE |
| 260 | -5.91 | -10.6910274964 | 55.28 | 80.5 | 36.2 | 5677 | 47.17924284 | DE |
Investor082
7分前
theorysuit
8分前
theorysuit
11分前
Investor082
11分前
theorysuit
12分前
HyGro
12分前
Investor082
14分前
tredenwater2
16分前
3331
17分前
BBANBOB
20分前
Flip it
20分前
3331
20分前
HyGro
23分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。